Company Description
Apnimed is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases.
Our sole clinical product candidate, AD109 (Oxnimbi), is an investigational, fixed-dose, anti-apneic neuromuscular modulator, combining a novel anti-muscarinic and a selective norepinephrine reuptake inhibitor (NRI) for the treatment of obstructive sleep apnea (OSA).
Oxnimbi is designed to target the neuromuscular defect of OSA by improving upper airway muscle activity to help maintain airway patency and prevent airway collapse during sleep.
Based on results from two registrational trials, we submitted a New Drug Application (NDA) for Oxnimbi to the U.S. Food and Drug Administration (FDA) in April 2026.
| Country | United States |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 65 |
| CEO | Kevin R. Lind |
Contact Details
Address: 39 John F. Kennedy Street, 4th Floor Cambridge, MA 02138 United States | |
| Phone | (617) 500-8880 |
| Website | apnimed.com |
Stock Details
| Ticker Symbol | APMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1745648 |
Key Executives
| Name | Position |
|---|---|
| Kevin R. Lind | Chief Executive Officer and Director |
| Michael Kelly | Chief Financial Officer |
| Dennis P. Molnar | President and Chief Operating Officer |
| John Cronin, M.D. | Chief Medical Officer |
| Graham Goodrich | Chief Commercial Officer |
| Barry Wohl | Chief Business Officer |
| Steven Spector, J.D. | Chief Legal Officer and Head of Corporate Affairs |
| Paul Sekhri | Director, Board Chair |
| Lawrence G. Miller, M.D. | Director, Vice Chair |
| Joseph Avellone, M.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 10, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 1, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Apr 22, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Mar 27, 2026 | D | Notice of Exempt Offering of Securities |
| Feb 17, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Dec 8, 2025 | D/A | Filing |
| Oct 1, 2025 | D/A | Filing |
| Sep 24, 2025 | D | Notice of Exempt Offering of Securities |
| Apr 24, 2025 | D | Notice of Exempt Offering of Securities |
| Jul 1, 2024 | DRS | [Cover] Draft Registration Statement |